The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…